Can a simple test predict CAR t success? new study hopes to find out

NCT ID NCT07472972

Recruiting now Knowledge-focused Sponsor: University of Zurich Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study is testing a new combination of blood tests, scans, and health checks to see if it can predict which lymphoma patients will respond well to CAR T cell therapy. Researchers will follow 50 patients with relapsed or hard-to-treat B-cell lymphoma who are already scheduled for standard CAR T treatment. The main goal is to see if the full test can be completed for each patient, not yet to change treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If successful, this tool could help doctors choose the best treatment for each lymphoma patient before starting CAR T therapy.
What could go wrong: This is a small, early feasibility study (50 participants) focused on whether the test can be completed, not yet on improving outcomes. The tool may not accurately predict responses in larger groups.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LYMPHOID HEMATOLOGICAL MALIGNANCIES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

B-cell non-Hodgkin lymphoma lymphoid neoplasm lymphoma Recurrence

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LYMPHOID HEMATOLOGICAL MALIGNANCIES LYMPHOMA

Contacts and locations

Locations

Universityhospital Zurich, Department of Medical Oncology and Hematology
RECRUITING

Zurich, Canton of Zurich, 8091, Switzerland

More trials for these conditions

Other studies related to the condition(s) this trial covers.